- American City Business Journals•10 days ago
On the heels of announcing a $45 million secondary public offering of the company’s common stock last month, Durham-based BioCryst Pharmaceuticals (BCRX) plans to move forward with a new trial for its hereditary angioedema (HAE) therapy BCX7353. The company said it will explore a new oral liquid for treating acute attacks in patients with hereditary angioedema. It added that it has received “initial regulatory approvals in Europe” for the clinical trial.
- GlobeNewswire•12 days ago
RESEARCH TRIANGLE PARK, N.C., April 12, 2017-- BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, announced today ...
- American City Business Journals•19 days ago
Durham-based BioCryst Pharmaceuticals (BCRX) stands to receive royalties from a new cancer therapy approved in Japan. The company announced that Mundipharma – with which it has a sub-licensing agreement – has received approval from the the Ministry of Health, Labor and Welfare in Japan for Mundesine, a therapy for the treatment of Peripheral T-Cell Lymphoma. “Under the terms of the agreement with Mundipharma, BioCryst will receive tiered royalties ranging from the mid- to high-single digit percentages of net sales of Mundesine,” BioCryst stated.
BCRX: Summary for BioCryst Pharmaceuticals, Inc. - Yahoo Finance
BioCryst Pharmaceuticals, Inc. (BCRX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
|Bid||6.21 x 100|
|Ask||7.44 x 700|
|Day's range||6.37 - 6.66|
|52-week range||2.49 - 9.25|
Trade prices are not sourced from all markets
|PE ratio (TTM)||-8.70|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|